Profound Medical Corp. (PROF)
| Market Cap | 262.77M +49.2% |
| Revenue (ttm) | 23.63M +65.3% |
| Net Income | -32.49M |
| EPS | -0.94 |
| Shares Out | 36.63M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 322,373 |
| Open | 6.46 |
| Previous Close | 6.88 |
| Day's Range | 6.16 - 7.22 |
| 52-Week Range | 4.80 - 8.95 |
| Beta | 0.56 |
| Analysts | Strong Buy |
| Price Target | 11.14 (+54.51%) |
| Earnings Date | Nov 5, 2026 |
About PROF
Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue. The company’s lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. It also provides Sonalleve, which combines real-t... [Read more]
Financial Performance
In 2025, Profound Medical's revenue was $16.10 million, an increase of 50.73% compared to the previous year's $10.68 million. Losses were -$42.57 million, 53.0% more than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for PROF stock is "Strong Buy." The 12-month stock price target is $11.14, which is an increase of 54.51% from the latest price.
News
What Profound Medical (PROF) Said on Its Q3 Earnings Call
Profound Medical NASDAQ: PROF reported an 86% increase in third-quarter revenue and raised its full-year revenue outlook, as sales of its TULSA-PRO equipment helped drive growth ahead of a planned lea...
Profound Medical (PROF) Q3 2026 Earnings Call Transcript
Revenue surged on system placements while a leadership transition reshapes the company's top job.
Profound Medical Corp. Announces Fall In Q3 Income
(RTTNews) - Profound Medical corp. (PROF) reported a profit for third quarter that Dropped, from last year
Profound Medical (PROF) Reports Q3 Loss, Beats Revenue Estimates
Profound Medical (PROF) delivered earnings and revenue surprises of -10.53% and +0.31%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Profound Medical reports Q3 EPS (21c), consensus (19c)
Reports Q3 revenue $9.83M, consensus $13.81M. “Revenue increased 86% year-over-year, gross margin reached 78%, and operating cash use declined substantially from the second quarter,” said Arun Menawat...
Profound Medical Earnings Call Transcript: Q3 2026
Q3 revenue rose 86% YoY to $9.8M, gross margin reached 78%, and operating cash use fell to $5.0M. FY 2026 revenue guidance is at least $25M, while Cook distribution and payer coverage support expansion plans.
Profound Medical Earnings release: Q3 2026
Profound Medical released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Profound Medical Quarterly report: Q3 2026
Profound Medical has published its Q3 2026 quarterly earnings report on November 5, 2026.
Profound Medical Reports Strong Third Quarter 2026 Results; Expands U.S. Distribution and Positions Leadership for Next Phase of Growth
Gross margin reaches 78%; cash used in operating activities declines 56% sequentially Profound expects full-year 2026 revenue to be at least $25.0 million; minimum gross margin projection for the year...
Profound Medical enters supply, distribution pact with Cook Medical
Profound Medical (PROF) announced that it has entered into a supply and distribution agreement with the iMRI Division of Cook Medical to expand U.S. sales of its Tulsa-Pro system. The…
Profound Medical and Cook Medical's iMRI Division Partner to Expand U.S. TULSA-PRO® Sales Channels and Drive Recurring Revenue Growth
New distribution agreement positions TULSA-PRO within the iMRI Suite offering through Cook Medical's Copernicus™ program, expanding Profound's commercial reach
Profound Medical Corp. Announces Montel Williams to Join Let’s Huddle Webinar on November 5, 2026
Profound Medical Corp. announced that television host, health advocate, and decorated U.S. Navy veteran Montel Williams will join the next Let’s Huddle webinar on November 5, 2026, at 3:00 p.m. ET. Ho...
Emmy-Award Winning Television Host Montel Williams to Join Next ‘Let’s Huddle’ Webinar
Patient advocacy initiative expands its reach with a nationally recognized voice on health, resilience and informed treatment decisions TORONTO, Oct. 22, 2026 (GLOBE NEWSWIRE) — Profound Medical Corp....
Emmy-Award Winning Television Host Montel Williams to Join Next ‘Let's Huddle' Webinar
TORONTO, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) today announced that Emmy Award-winning television host, health advocate and deco...
TULSA Abstracts at the 15th Interventional MRI Symposium Strengthen Real-World Evidence, Clinical Differentiation, and Platform Expansion Opportunity
TORONTO, Oct. 14, 2026 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) today announced that five abstracts presented at the 15th Interventional MRI (“iMR...
TULSA Abstracts at the 15th Interventional MRI Symposium Strengthen Real-World Evidence, Clinical Differentiation, and Platform Expansion Opportunity
TORONTO, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) today announced that five abstracts presented at the 15th Interventional MRI (“iM...
Profound Medical, Telix Pharma Sign Co-Education Deal To Advance PSMA-Informed Prostate Care
(RTTNews) - Friday, Profound Medical Corp. (PROF) and Telix Pharmaceuticals Limited (TLX) announced a co-education agreement to educate physicians and prostate cancer centers on the complementary role...
Profound Medical enters co-education agreement with Telix Pharmaceuticals
Profound Medical (PROF) announced it is entering into a co-education agreement with Telix Pharmaceuticals (TLX). The agreement establishes a framework through which the companies intend to educate uro...
Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care
Collaboration will educate physicians and prostate cancer centers on the complementary roles of Telix's PSMA-PET molecular imaging technologies and Profound's MRI-guided TULSA-PRO ® Agreement provides...
Strength Seen in Profound Medical (PROF): Can Its 21.7% Jump Turn into More Strength?
Profound Medical (PROF) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price inc...
Profound Medical sees Q3 revenue $9.8M-$10M, consensus $9.56M
Sees Q3 gross margin over 70%. “The significant increase in revenue we expect to report this quarter represents a historic milestone for Profound, reflecting the strong commercial momentum building be...
Profound Medical Reports Strong Preliminary Third Quarter 2026 Revenue
Anticipates Q3-2026 revenue of $9.8 million to $10.0 million, exceeding Bloomberg analyst consensus by approximately 45% to 47% TORONTO, Oct. 07, 2026 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ...
Profound Medical Reports Strong Preliminary Third Quarter 2026 Revenue
Anticipates Q3-2026 revenue of $9.8 million to $10.0 million, exceeding Bloomberg analyst consensus by approximately 45% to 47% Anticipates Q3-2026 revenue of $9.8 million to $10.0 million, exceeding ...
Profound Medical initiated with a Buy at Titan Partners
Titan Partners initiated coverage of Profound Medical (PROF) with a Buy rating and $12 price target The company’s TULSA-PRO facilitates MRI-guided, incision-free prostate ablation and is supported by ...
Profound Medical to Participate in Lake Street’s 10th Annual Best Ideas Growth Conference
TORONTO, Sept. 03, 2026 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative i...